Targeting interleukin-17 in patients with active rheumatoid arthritis: Rationale and clinical potential

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 3, 2013, Pages 141-152

  Kellner, Herbert ^a  

^a Hospital Neuwittelsbach   (Grenada)

Author keywords

interleukin 17A; methotrexate; rheumatoid arthritis; secukinumab

Indexed keywords

BRODALUMAB; INTERLEUKIN 17; IXEKIZUMAB; METHOTREXATE; PLACEBO; PREDNISONE; SECUKINUMAB;

ARTICLE; CELL DIFFERENTIATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; NONHUMAN; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SYNOVIAL FLUID; TH17 CELL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO;

EID: 84887444732     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13485328     Document Type: Article

References (71)

1. Aaltonen K. Virkki L. Malmivaara A. Konittinen Y. Nordström D. Blom M. (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PloS ONE 7: e30275.
2. Acosta-Rodriguez E. Napolitani G. Lanzavecchia A. Sallusto F. (2007) Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942–949.
3. Adamopoulos I. Chao C. Geissler R. Laface D. Blumenschein W. Iwakura I. et al. (2010) Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 12: R29.
4. Alonso-Ruiz A. Pijoan J. Ansuategui E. Urkaregi A. Calabozo M. Quintana A. (2008) Tumor necrosis factor α drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9: 52.
5. Alzabin S. Abraham S. Taher T. Palfreeman A. Hull D. McNamee R. et al. (2012) Incomplete responses of inflammatory arthritis to TNFα blockade is associated with the Th 17 pathway. Ann Rheum Dis 71: 1741–1748.
6. Annunziato F. Romagnani S. (2009) Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 11: 257.
7. Arroyo-Villa I. Bautista-Caro M. Balsa A. Aguado-Acin P. Nuño L. Bonilla-Hernán M. et al. (2012) Frequency of Th 17 CD4+ T cells in early rheumatoid arthritis: a marker of anti-CCP seropositivity. PloS ONE 7: e42189.
8. Bovenschen H. van de Kerkhof P. van Erp P. Woestenenk R. Joostenm I. Koenen H. (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131: 1853–1860.
9. Bush K. Farmer K. Walker J. Kirkham B. (2002) Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG 1 Fc fusion protein. Arthritis Rheum 46: 802–805.
10. Chabaud M. Durand J. Buchs N. Fossiez F. Page G. Frappart L. et al. (1999) Human interleukin-17: a T-cell derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42: 963–970.
11. Chabaud M. Lubberts E. Joosten L. van den Berg W. Miossec P. (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 3: 168–177.
12. Chang S. Dong C. (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17: 435–440.
13. Chao C. Chen S. Adamopoulos I. Davis N. Hong K. Vu A. et al. (2011) Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44: 243–252.
14. Chen D. Chen Y. Chen H. Hsieh C. Lin C. Lan J. (2011) Increasing levels of circulating Th 17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 13: R126.
15. Churchill M. Flores-Suarez L. Wallace D. Phillips K. Martin R. Cardiel M. et al. (2012) A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab (AMG 827), a human anti-interleukin 17 receptor (IL-17R) antibody, in rheumatoid arthritis. Arthritis Rheum 64(10 Suppl.): S555.
16. Dharmapatni A. Smith M. Crotti T. Holding C. Vincent C. Weedon H. et al. (2011) TWEAK and Fn 14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther 13: R51.
17. Finckh A. Simard J. Gabay C. Guerne P. (2006) Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65: 746–752.
18. Gaffen S. (2009) Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 9: 556–567.
19. Genovese M. Durez P. Richards H. Supronik J. Dokoupilova E. Mazurov V. et al. (2012 a) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 23 June (Epub ahead of print): doi: 10.1136/annrheumdis-2012-201601.
20. Genovese M. Greenwald M. Cho C. Berman A. Jin L. Cameron G. et al. (2011) A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors [abstract]. Arthritis Rheum 63(10 Suppl.): S1017.
21. Genovese M. Kellner H. Durez P. Codding C. Ligozio G. Richards H. et al. (2012 b) Secukinumab treatment improves ACR50, HAQ-DI and EULAR remission rates in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 71(Suppl. 3): 191.
22. Genovese M. van den Bosch F. Roberson S. Bojin S. Biagini I. Ryan P. et al. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 62: 929–939.
23. Gnanasakthy A. Kosinski M. Genovese M. Mallya U. Mpofu S. (2012) Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab [abstract]. Ann Rheum Dis 71(Suppl. 3): 666.
24. Gullick N. Scott D. (2011) Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 25: 469–483.
25. Harrington L. Hatton R. Mangan P. Turner H. Murphy T. Murphy K. et al. (2005) Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123–1132.
26. Hot A. Zrioual S. Toh M. Lenief V. Miossec P. (2011) IL-17A-versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 70: 341–348.
27. Hueber A. Asquith D. Miller A. Reilly J. Kerr S. Leipe J. et al. (2010 a) Cutting edge: mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184: 3336–3340.
28. Hueber W. Patel D. Dryja T. Wright A. Koroleva I. Bruin G. et al. (2010 b) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52ra72.
29. Ichiyama K. Yoshida H. Wakabayashi Y. Chinen T. Saeki K. Nakaya M. et al. (2008) Foxp 3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J Biol Chem 283: 17003–17008.
30. Ishiguro A. Akiyama T. Adachi H. Inoue J. Nakamura Y. (2011) Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum 63: 455–466.
31. Iwakura Y. Ishigame H. Saijo S. Nakae S. (2011). Functional specialization of interleukin-17 family members. Immunity 34: 149–162.
32. Kisand K. Bøe Wolff A. Podkrajsek K. Tserel L. Link M. Kisand K. et al. (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207: 299–308.
33. Koenders M. Lubberts E. Oppers-Walgreen B. van den Bersselaar L. Helsen M. Di Padova F. et al. (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 167: 141–149.
34. Koenen H. Smeets R. Vink P. van Rijssen E. Boots A. Joosten I. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17–producing cells. Blood 112: 2340–2352.
35. Koivuniemi R. Paimela L. Leirisalo-Repo M. (2009) Causes of death in patients with rheumatoid arthritis from 1971 to 1991 with special reference to autopsy. Clin Rheumatol 28: 1443–1447.
36. Korn T. Bettelli E. Oukka M. Kuchroo V. (2009) IL-17 and Th 17 cells. Annu Rev Immunol 27: 485–517.
37. Langrish C. Chen Y. Blumenschein W. Mattson J. Basham B. Sedgwick J. et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233–240.
38. Leonardi C. Matheson R. Zacharie C. Cameron G. Li L. Edson-Heredia E. et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190–1199.
39. Lubberts E. Joosten L. Oppers B. van den Bersselaar L. Coenen-de Roo C. Kolls J. et al. (2001) IL-1–independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167: 1004–1013.
40. Lubberts E. Koenders M. Oppers-Walgreen B. van den Bersselaar L. Coenen-de Roo C. Joosten L. et al. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650–659.
41. McInnes I. Schett G. (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205–2219.
42. Metawi S. Abbas D. Kamal M. Ibrahim M. (2011) Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30: 1201–1207.
43. Miossec P. Korn T. Kuchroo V. (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888–898.
44. Moran E. Mullan R. McCormick J. Connolly M. Sullivan O. FitzGerald O. et al. (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biological therapies. Arthritis Res Ther 11: R113.
45. Nakae S. Nambu A. Sudo K. Iwakura Y. (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173–6177.
46. Onishi R. Gaffen S. (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129: 311–321.
47. Papp K. Langley R. Sigurgeirsson B. Abe M. Baker D. Konno P. et al. (2012 a) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168: 412–421.
48. Papp K. Leonardi C. Menter A. Ortonne J. Krueger J. Kricorian G. et al. (2012 b) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366: 1181–1189.
49. Pappu R. Ramirez-Carrozzi V. Ota N. Ouyang W. Hu Y. (2010) The IL-17 family cytokines in immunity and disease. J Clin Immunol 30: 185–195.
50. Park H. Li Z. Yang X. Chang S. Nurieva R. Wang Y. et al. (2005) A distinct lineage of CD 4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133–1141.
51. Park J. Park M. Lee S. Oh H. Lim M. Cho W. et al. (2012) TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine 60: 143–149.
52. Pavelka K. Chon Y. Newmark R. Erondu N. Lin S. (2012) A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 64(10 Suppl.): S362.
53. Plater-Zyberk C. Joosten L. Helsen M. Koenders M. Baeuerle P. van den Berg W. (2009) Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor α-independent mouse model. Ann Rheum Dis 68: 721–728.
54. Pöllinger B. Junt T. Metzler B. Walker U. Tyndall A. Allard C. et al. (2011) Th 17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 186: 2602–2612.
55. Puel A. Cypowyj S. Bustamante J. Wright J. Liu L. Lim H. et al. (2011) Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332: 65–68.
56. Puel A. Döffinger R. Natividad A. Chrabieh M. Barcenas-Morales G. Picard C. et al. (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207: 291–297.
57. Rich P. Sigurgeirsson B. Thaci D. Ontonne J. Paul C. Schopf R. et al. (2012) Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 168: 402–411.
58. Rickel E. Siegel L. Yoon B. Rottman J. Kugler D. Swart D. et al. (2008) Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol 181: 4299–4310.
59. Rouvier E. Luciani M. Mattéi M. Denizot F. Golstein P. (1993). CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150: 5445–5456.
60. Salliot C. Finckh A. Katchamart W. Lu Y. Sun Y. Bombardier C. et al. (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266–271.
61. Sato K. Suematsu A. Okamoto K. Yamaguchi A. Morishita Y. Kadono Y. et al. (2006) Th 17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682.
62. Smolen J. Landewé R. Breedveld F. Dougados M. Emery P. Gaujoux-Viala C. et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69: 964–975.
63. Strand V. Genovese M. Mallya U. Richards H. Mpofu S. (2012). Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: results of a dose-finding study [abstract]. Ann Rheum Dis 71(Suppl. 3): 671.
64. Suurmond J. Dorjée A. Boon M. Knol E. Huizinga T. Toes R. et al. (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13: R150.
65. van Venrooij W. van Beers J. Pruijn G. (2011) Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 7: 391–398.
66. Wilson N. Boniface K. Chan J. McKenzie B. Blumenschein W. Mattson J. et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950–957.
67. Wright J. Guo Y. Quazi A. Luxenberg D. Bennett F. Ross J. et al. (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem 282: 13447–13455.
68. Yao Z. Fanslow W. Seldin M. Rousseau A. Painter S. Comeau M. et al. (1995 a) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3: 811–821.
69. Yao Z. Painter S. Fanslow W. Ulrich D. Macduff B. Spriggs M. et al. (1995 b) Human IL-17: a novel cytokine derived from T cells. J Immunol 155: 5483–5486.
70. Zhang W. Anis A. (2011) The economic burden of rheumatoid arthritis: beyond health care costs. Clin Rheumatol 30(Suppl. 1): S25–S32.
71. Ziolkowska M. Koc A. Luszczykiewicz G. Ksiezopolska-Pietrzak K. Klimczak E. Chwalinska-Sadowska H. et al. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol 164: 2832–2838.